Table 2 Distribution of biomarkers in 151 NSCLC patients according to clinicopathological characteristics

From: Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT

  

TS-positive

OPRT-positive

DPD-positive

Characteristics

n

(%)

P -value

(%)

P -value

(%)

P -value

Smoking

 Nonsmoker

51

52.0

0.4260

70.6

0.8411

54.9

0.1167

 Smoker

100

58.8

 

69.0

 

40.0

 

Tumour status

 T1, T2

102

56.9

0.3626

73.5

0.1240

40.2

0.1211

 T3, T4

49

49.0

 

61.2

 

55.1

 

Nodal status

 N0

88

48.9

0.1127

67.0

0.4319

38.6

0.0887

 N1, N2

63

61.9

 

73.0

 

54.0

 

Pathological stage

 Stage I

62

53.2

0.7905

66.1

0.4886

35.5

0.0757

 Stage II

28

50.0

 

78.6

 

42.9

 

 Stage III

61

57.4

 

68.9

 

55.7

 

Differentiation

 Well

46

60.9

0.1888

65.2

0.4395

43.5

0.9338

 Moderately

54

44.4

 

75.9

 

44.4

 

 Poorly

51

58.8

 

66.7

 

47.1

 

Histology

 Adenocarcinoma

84

42.9

0.0063

69.0

0.3170

47.6

0.5025

 Squamous cell carcinoma

56

69.6

 

76.8

 

39.3

 

 Large cell carcinoma

11

63.6

 

36.4

 

54.5

 

 Neoadjuvant chemotherapy

       

 Neoadjuvant MVP

30

60.0

0.3700

53.3

0.0943

50.0

0.6691

 Neoadjuvant CBDCA/PTX

9

33.3

 

77.8

 

33.3

 

 Without neoadjuvant

112

54.5

 

73.2

 

44.6

 

Total number of patients

151

54.3

 

69.5

 

45.0

 
  1. CBDCA/PTX=carboplatin/paclitaxel; MVP=mitomycin/vinblastin/cisplatin; NSCLC=non-small-cell lung cancer.
Back to article page